Antibody therapies have been fast gaining traction through the years. Its landmark use case was in 1986 when the Food and Drug Administration (FDA) approved the first monoclonal antibody therapy to prevent transplant rejection in patients.
While effective in improving patient outcomes and lower side effects, these antibodies are distinct, large, and complex, making it incredibly difficult to accurately determine the optimal set of antibodies for the wide spectrum of diseases.
Traditional laboratory-based systems are often laborious, costly, and prone to failure. Even after screening up to thousands of antibody candidates, these methods only yield a 10% success rate going into the clinical trial stage.
Aridni Shah and Trisha Chatterjee who met at Entrepreneur First (“EF”) decided to work together to tackle this colossal challenge. They believe that leveraging artificial intelligence technology can game-change the antibody screening process and founded immunitoAI.
We spoke to them to learn more about their EF journey and their shared aspirations for their biotechnology company.